Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?
This article was originally published in The Pink Sheet Daily
With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.
You may also be interested in...
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.